LLY

785.5

-1.33%↓

JNJ

151.02

-1.65%↓

ABBV

186.23

-0.54%↓

NVO

74.48

-0.29%↓

UNH

309.73

+0.41%↑

LLY

785.5

-1.33%↓

JNJ

151.02

-1.65%↓

ABBV

186.23

-0.54%↓

NVO

74.48

-0.29%↓

UNH

309.73

+0.41%↑

LLY

785.5

-1.33%↓

JNJ

151.02

-1.65%↓

ABBV

186.23

-0.54%↓

NVO

74.48

-0.29%↓

UNH

309.73

+0.41%↑

LLY

785.5

-1.33%↓

JNJ

151.02

-1.65%↓

ABBV

186.23

-0.54%↓

NVO

74.48

-0.29%↓

UNH

309.73

+0.41%↑

LLY

785.5

-1.33%↓

JNJ

151.02

-1.65%↓

ABBV

186.23

-0.54%↓

NVO

74.48

-0.29%↓

UNH

309.73

+0.41%↑

Search

Arbutus Biopharma Corp

Open

3.46 -0.86

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.43

Max

3.55

Schlüsselkennzahlen

By Trading Economics

Einkommen

-12M

-25M

Verkäufe

190K

1.8M

EPS

-0.182

Gewinnspanne

-1,390.363

Angestellte

44

EBITDA

-12M

-24M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+39.66% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

44M

686M

Vorheriger Eröffnungskurs

4.32

Vorheriger Schlusskurs

3.46

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Arbutus Biopharma Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Juni 2025, 14:44 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Orders Safran to Sell Assets to Proceed with Buy of Collins Aerospace Business

17. Juni 2025, 23:43 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

17. Juni 2025, 23:34 UTC

Market Talk

Gold Steady, Underpinned by Ongoing Geopolitical Tensions -- Market Talk

17. Juni 2025, 23:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Juni 2025, 23:22 UTC

Market Talk

Global Energy Roundup: Market Talk

17. Juni 2025, 23:22 UTC

Market Talk

Meridian Energy Set to Draw Line Under 'Annus Horribilis' -- Market Talk

17. Juni 2025, 23:17 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tourism Holdings Likely to Seek Higher Offer -- Market Talk

17. Juni 2025, 23:05 UTC

Market Talk

Fletcher Building Could Signal Improved Shareholder Returns -- Market Talk

17. Juni 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

17. Juni 2025, 22:58 UTC

Market Talk

Australian Treasurer Chalmers Expected to Outline Second-Term Reform Agenda -- Market Talk

17. Juni 2025, 22:55 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

XRG Has a Good Argument for Regulatory Approval of Santos Deal -- Market Talk

17. Juni 2025, 22:31 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Lifeway Foods CEO Not Surprised by Takeover Interest -- Market Talk

17. Juni 2025, 22:14 UTC

Wichtige Markttreiber

Bitdeer Technologies Group Shares Fall on Note Offering

17. Juni 2025, 19:49 UTC

Market Talk

Natural Gas Slow Down Gains -- Market Talk

17. Juni 2025, 19:34 UTC

Market Talk

Oil Rises On Israel-Iran Conflict Uncertainty -- Market Talk

17. Juni 2025, 19:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Juni 2025, 19:10 UTC

Market Talk

Dollar Strengthens, Treasury Yields Fall in Risk-Off Trade -- Market Talk

17. Juni 2025, 18:41 UTC

Market Talk

Slowdown in US Consumer Spending Expected -- Market Talk

17. Juni 2025, 18:15 UTC

Market Talk

Gold Inches Down as Profit-Taking Seen -- Market Talk

17. Juni 2025, 17:44 UTC

Market Talk

Analysts Forecast Record-High Ethanol Output -- Market Talk

17. Juni 2025, 16:37 UTC

Market Talk

A Buy-Canadian Policy Could Support Steel Producers -- Market Talk

17. Juni 2025, 16:30 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

17. Juni 2025, 16:30 UTC

Market Talk

Canada Seen Likely to Drop Digital-Services Tax -- Market Talk

17. Juni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

17. Juni 2025, 16:15 UTC

Market Talk

Base Metal Prices Mixed on Risk-Off Sentiment -- Market Talk

17. Juni 2025, 16:12 UTC

Market Talk

Gold Futures Fall as Safe-haven Demand Retreats -- Market Talk

17. Juni 2025, 14:54 UTC

Market Talk

Oil Rises on Continued Israel-Iran Conflict -- Market Talk

17. Juni 2025, 14:47 UTC

Market Talk

European Gas Climbs on Middle East Risks, EU Russian Ban Proposal -- Market Talk

17. Juni 2025, 14:41 UTC

Market Talk

Natural Gas Extends Climb -- Market Talk

17. Juni 2025, 14:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Arbutus Biopharma Corp Prognose

Kursziel

By TipRanks

39.66% Vorteil

12-Monats-Prognose

Durchschnitt 5 USD  39.66%

Hoch 5 USD

Tief 5 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arbutus Biopharma Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

3.255 / 3.365Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.